A game changing technology with a host of applications in medicine and biotechnology, including gene therapy, stem cell modification, protein production and plant breeding.Savvy business management with deals and alliances that include DOW, Sigma Aldrich and Genentech.A rapidly developing pipeline that includes angiogenesis, neural regeneration and an entirely novel approach to cure AIDS Sound science published in top journals and a scientific advisory board that includes a Nobel laureate.They control the intellectual property rights.They acquired their sole competitor.Targeting DNA �provokes biological outcomes not achievable at the RNA or protein level� � offering an entirely new way to treat disease. Medical breakthroughs will come from combining ZFP technology with stem cells and gene therapyPromising results for SB509 can be applied in multiple indications (including DN, PAD, ALS and SCI).The market for DN alone is in excess of $1 billion per annum.The market for a pain repressor is $750 per annumNew product candidates can be developed in weeks.Recent results in stem cells promise widespread dissemination of the technology and royalties from Sigma Aldrich.Sigma Aldrich royalties could exceed $100 million per annum. Agricultural biotechnology is poised for explosive development DOW milestones are being met ahead of time, with a deal in the making.Monetizing the technology in agriculture and biotechnology offsets the costs of clinical development Dow royalties could add up to $100 million per annum.Multiple licensing opportunities for pharmaceutical protein production.
read this everyday..aar
Agreed, must read along with the IPs, JMP Securities and Cantor reports!
A must read everyday..aar